Antonio Marra
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
Antonio Marra
Jun 30, 2024, 10:58 |
Insight
Eleonora Nicolò: Our analysis on safety and efficacy of new drugs investigated in phase I/II clinical trials by age
Eleonora Nicolò, Research Fellow at Weill Cornell Medicine, shared a post on X: "Just out…
May 29, 2024, 23:08 |
Blog
Antonio Marra: I strongly endorse Giuseppe Curigliano's vision as ESMO President
Antonio Marra, Medical Oncologist at the European Institute of Oncology, shared on LinkedIn: "Voting for ESMO…
Mar 23, 2024, 23:31 |
Blog
Antonio Marra: Our review on current use and future development of PARP inhibitors in breast cancer just out in JAMA Oncology
Antonio Marra, Medical Oncologist at the European Institute of Oncology, on LinkedIn: “Excited to see…
Aug 27, 2023, 18:59 |
Insight
Antonio Marra: In an analysis of more than 28k pts, pancreatic acinar cell carcinoma was the cancer type with the highest prevalence of gBRCA2 and HRD features.
Quoting Antonio Marra, medical oncologist at the European Institute of Oncology, on Twitter: "Our latest…
All:
4
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube